MCT1 Is a New Prognostic Biomarker and Its Therapeutic Inhibition Boosts Response to Temozolomide in Human Glioblastoma

MCT1 Is a New Prognostic Biomarker and Its Therapeutic Inhibition Boosts Response to Temozolomide in Human Glioblastoma

<i>Background:</i> Glioblastomas (GBMs) present remarkable metabolism reprograming, in which many cells display the “Warburg effect”, with the production of high levels of lactate that are extruded to the tumour microenvironment by monocarboxylate transporters (MCTs). We described previo...

Full description

Bibliographic Details
Main Authors: Vera Miranda-Gonçalves, Céline S. Gonçalves, Sara Granja, Joana Vieira de Castro, Rui M. Reis, Bruno M. Costa, Fátima Baltazar
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Cancers
Subjects:
monocarboxylate transporters
glioblastoma
lactate
Warburg effect
prognostic biomarker
Online Access:https://www.mdpi.com/2072-6694/13/14/3468

Internet

https://www.mdpi.com/2072-6694/13/14/3468

Similar Items